Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $56.82

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus rating of "Buy" by the twelve analysts that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $56.82.

Several equities analysts have recently commented on MIRM shares. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a research report on Thursday, August 8th. Cantor Fitzgerald upped their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, August 8th. Leerink Partners raised their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an "outperform" rating in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Friday, October 11th.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 65.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company's stock worth $358,000 after purchasing an additional 3,639 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. Values First Advisors Inc. boosted its stake in shares of Mirum Pharmaceuticals by 20.1% in the 3rd quarter. Values First Advisors Inc. now owns 23,725 shares of the company's stock worth $925,000 after buying an additional 3,971 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Mirum Pharmaceuticals by 10.8% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company's stock worth $4,526,000 after purchasing an additional 11,284 shares during the last quarter. Finally, Creative Planning bought a new position in Mirum Pharmaceuticals during the third quarter valued at about $249,000.

Mirum Pharmaceuticals Trading Down 1.2 %

Shares of MIRM stock traded down $0.47 during mid-day trading on Friday, hitting $38.89. 195,510 shares of the company's stock were exchanged, compared to its average volume of 570,946. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $45.23. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The stock has a 50-day simple moving average of $40.34 and a two-hundred day simple moving average of $34.24. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -10.48 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05). The company had revenue of $77.90 million for the quarter, compared to analyst estimates of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The company's revenue for the quarter was up 107.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.92) EPS. Equities analysts expect that Mirum Pharmaceuticals will post -1.75 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.